Cancel

Drug Trends

(No Reviews)
22/32 King St, Randwick NSW 2031, Australia

Drug Trends is located in Randwick City Council of New South Wales state. On the street of King Street and street number is 32. To communicate or ask something with the place, the Phone number is (02) 9385 0333. You can get more information from their website.
The coordinates that you can use in navigation applications to get to find Drug Trends quickly are -33.9055841 ,151.236675

Contact and Address

Address: 22/32 King St, Randwick NSW 2031, Australia
Postal code: 2031
Phone: (02) 9385 0333
Website: http://drugtrends.org.au/

Location & routing

Get Directions

Reviews

There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Drug Trends, use the form below and your opinion, advice or comment will appear in this space.

Write a Review


Drug Trends On the Web

Drug Trends | NDARC - National Drug and Alcohol Research Centre

Drug Trends triangulates data from various sources to identify emerging problems in substance use in Australia. ... Ph 02 9385 0227. rachels@unsw.edu.au. CONNECT WITH US ... 9385 0333 F +61 (2) 9385 0222 E ndarc@unsw.edu.au Postal Address NDARC


Drug Trends - 22/32 King St, Randwick NSW 2031, Australia

Drug Trends is located in Randwick City Council of New South Wales state. On the street of King Street and street number is 32. To communicate or ask something with the place, the Phone number is (02) 9385 0333. You can get more information from their website.


Emerging Drug Trends | Get Smart About Drugs

Emerging Drug Trends Emerging Drug Trends. Last Updated: Monday August 16, 2021. Report: Drug Overdose Deaths Surpass 100,000 (Associated Press, November 18) For the first time ever, drug overdose deaths in the U.S. surpassed 100,000 during a 12-month period. Teens and vaping marijuana: Understanding the dangers of 'dabbing' ...


National Drug Trends reports to be released at NDARC Symposium

Media contacts: Marion Downey P: (02) 9385 0333 | 0401 713 850 | m.downey@unsw.edu.au ... according to the 2018 Drug Trends Reports from the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney. The reports will be released at the NDARC Annual Symposium at UNSW Sydney on Monday, 8 October 2018. Research to be presented by Dr Caitlin ...


Drug Trend Report - Overall Trend | CVS Health Payor Solutions

Percent of clients with less than 10% specialty drug trend in 2021, and in the past two years. The remainder of the insights featured in the report align to data shared on February 24, 2022, reflecting year-to-date Q3 2021. This report provides an overview of performance for commercial clients of CVS Health's pharmacy benefits manager (PBM).


The Annual National Drug Trends Conference - atoda.org.au

The Annual National Drug Trends Conference. October 14, 2015 ... Organizer National Drug & Alcohol Research Centre (NDARC) Phone: (02) 9385 0333


Drug Trends Bulletin: Crystal methamphetamine and use of commercial ...

The latest Drug Trends bulletin looked at Crystal Methamphetamine use and the use of commercial pipes. The Ecstasy and Related Drugs Reporting System (EDRS) is a national drug monitoring system intended to identify emerging trends of local and national concern in illicit drug markets, and form part of Drug Trends.. The aims of this bulletin are to examine (i) recent (past six-month) use of ...


3 New Drug Trends Among Youth to Watch in 2022… and What You Can Do ...

This entry was posted in Addiction News, Drug Abuse and tagged how to keep kids off drugs, new drug trends 2022, new drug trends among youth 2022, snapchat drugs on December 2, 2021 by Justin Baksh, LMHC, MCAP, Chief Clinical Officer. Kids are turning to drug use at a very early age. Unfortunately, statistics show that things are getting worse:


Drug Trends - Home

Drug Trends. 146 likes. We research & relay vital information regarding trends in Australia's drug markets.


2021 and Onward | Drug Trend Report | Evernorth

Utilization increases may be influenced by new patients using existing medications to treat psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis, as well as by the approval of new drugs—abrocitinib and deucravacitinib—in 2021. Several lower cost biosimilars for Humira ® (adalimumab) are due to enter the market in 2023.